AAAAAA

   
Results: 1-22 |
Results: 22
Combination therapy with saquinavir soft gelatin capsules in children withhuman immunodeficiency virus infection
Authors: Kline, MW Brundage, RC Fletcher, CV Schwarzwald, H Calles, NR Buss, NE Snell, P Delora, P Eason, M Jorga, K Craig, C Duff, F
Citation: Mw. Kline et al., Combination therapy with saquinavir soft gelatin capsules in children withhuman immunodeficiency virus infection, PEDIAT INF, 20(7), 2001, pp. 666-671
Pharmacological basis for concentration-controlled therapy with zidovudine, lamivudine, and indinavir
Authors: Kakuda, TN Page, LM Anderson, PL Henry, K Schacker, TW Rhame, FS Acosta, EP Brundage, RC Fletcher, CV
Citation: Tn. Kakuda et al., Pharmacological basis for concentration-controlled therapy with zidovudine, lamivudine, and indinavir, ANTIM AG CH, 45(1), 2001, pp. 236-242
Pharmacodynamics of human immunodeficiency virus type 1 protease inhibitors
Authors: Acosta, EP Kakuda, TN Brundage, RC Anderson, PL Fletcher, CV
Citation: Ep. Acosta et al., Pharmacodynamics of human immunodeficiency virus type 1 protease inhibitors, CLIN INF D, 30, 2000, pp. S151-S159
Evidence of a source of HIV type 1 within the central nervous system by ultraintensive sampling of cerebrospinal fluid and plasma
Authors: Haas, DW Clough, LA Johnson, BW Harris, VL Spearman, P Wilkinson, GR Fletcher, CV Fiscus, S Raffanti, S Donlon, R McKinsey, J Nicotera, J Schmidt, D Shoup, RE Kates, RE Lloyd, RM Larder, B
Citation: Dw. Haas et al., Evidence of a source of HIV type 1 within the central nervous system by ultraintensive sampling of cerebrospinal fluid and plasma, AIDS RES H, 16(15), 2000, pp. 1491-1502
Semen and serum pharmacokinetics of zidovudine and zidovudine-glucuronide in men with HIV-1 infection
Authors: Anderson, PL Noormohamed, SE Henry, K Brundage, RC Balfour, HH Fletcher, CV
Citation: Pl. Anderson et al., Semen and serum pharmacokinetics of zidovudine and zidovudine-glucuronide in men with HIV-1 infection, PHARMACOTHE, 20(8), 2000, pp. 919-924
Competing drug-drug interactions among multidrug antiretroviral regimens used in the treatment of HIV-infected subjects: ACTG 884
Authors: Fletcher, CV Acosta, EP Cheng, HL Haubrich, R Fischl, M Raasch, R Mills, C Hu, XJ Katzenstein, D Remmel, RP Gulick, RM
Citation: Cv. Fletcher et al., Competing drug-drug interactions among multidrug antiretroviral regimens used in the treatment of HIV-infected subjects: ACTG 884, AIDS, 14(16), 2000, pp. 2495-2501
Indinavir plasma protein binding in HIV-1-infected adults
Authors: Anderson, PL Brundage, RC Bushman, L Kakuda, TN Remmel, RP Fletcher, CV
Citation: Pl. Anderson et al., Indinavir plasma protein binding in HIV-1-infected adults, AIDS, 14(15), 2000, pp. 2293-2297
Zidovudine triphosphate and lamivudine triphosphate concentration-responserelationships in HIV-infected persons
Authors: Fletcher, CV Kawle, SP Kakuda, TN Anderson, PL Weller, D Bushman, LR Brundage, RC Remmel, RP
Citation: Cv. Fletcher et al., Zidovudine triphosphate and lamivudine triphosphate concentration-responserelationships in HIV-infected persons, AIDS, 14(14), 2000, pp. 2137-2144
A risk-benefit evaluation of aciclovir for the treatment and prophylaxis of herpes simplex virus infections
Authors: Leflore, S Anderson, PL Fletcher, CV
Citation: S. Leflore et al., A risk-benefit evaluation of aciclovir for the treatment and prophylaxis of herpes simplex virus infections, DRUG SAFETY, 23(2), 2000, pp. 131-142
Pharmacologic characteristics of indinavir, didanosine, and stavudine in human immunodeficiency virus-infected children receiving combination therapy
Authors: Fletcher, CV Brundage, RC Remmel, RP Page, LM Weller, D Calles, NR Simon, C Kline, MW
Citation: Cv. Fletcher et al., Pharmacologic characteristics of indinavir, didanosine, and stavudine in human immunodeficiency virus-infected children receiving combination therapy, ANTIM AG CH, 44(4), 2000, pp. 1029-1034
Patterns of plasma human immunodeficiency virus type 1 RNA response to highly active antiretroviral therapy in infected children
Authors: Spector, SA Hsia, K Yong, FH Cabral, S Fenton, T Fletcher, CV McNamara, J Mofenson, LM Starr, SE
Citation: Sa. Spector et al., Patterns of plasma human immunodeficiency virus type 1 RNA response to highly active antiretroviral therapy in infected children, J INFEC DIS, 182(6), 2000, pp. 1769-1773
Recombinant CD4-IgG2 in human immunodeficiency virus type 1-infected children: Phase 1/2 study
Authors: Shearer, WT Israel, RJ Starr, S Fletcher, CV Wara, D Rathore, M Church, J DeVille, J Fenton, T Graham, B Samson, P Staprans, S McNamara, J Moye, J Maddon, PJ Olson, WC
Citation: Wt. Shearer et al., Recombinant CD4-IgG2 in human immunodeficiency virus type 1-infected children: Phase 1/2 study, J INFEC DIS, 182(6), 2000, pp. 1774-1779
Randomized study of saquinavir with ritonavir or nelfinavir together with delavirdine, adefovir, or both in human immunodeficiency virus-infected adults with virologic failure on indinavir: AIDS Clinical Trials Group study 359
Authors: Gulick, RM Hu, XJ Fiscus, SA Fletcher, CV Haubrich, R Cheng, HL Acosta, E Lagakos, SW Swanstrom, R Freimuth, W Snyder, S Mills, C Fischl, M Pettinelli, C Katzenstein, D
Citation: Rm. Gulick et al., Randomized study of saquinavir with ritonavir or nelfinavir together with delavirdine, adefovir, or both in human immunodeficiency virus-infected adults with virologic failure on indinavir: AIDS Clinical Trials Group study 359, J INFEC DIS, 182(5), 2000, pp. 1375-1384
Single-dose safety, pharmacology, and antiviral activity of the human immunodeficiency virus (HIV) type 1 entry inhibitor PRO 542 in HIV-infected adults
Authors: Jacobson, JM Lowy, I Fletcher, CV O'Neill, TJ Tran, DNH Ketas, TJ Trkola, A Klotman, ME Maddon, PJ Olson, WC Israel, RJ
Citation: Jm. Jacobson et al., Single-dose safety, pharmacology, and antiviral activity of the human immunodeficiency virus (HIV) type 1 entry inhibitor PRO 542 in HIV-infected adults, J INFEC DIS, 182(1), 2000, pp. 326-329
Use of human immunodeficiency virus (HIV) human hyperimmune immunoglobulinin HIV type 1-infected children (Pediatric AIDS Clinical Trials Group Protocol 273)
Authors: Stiehm, ER Fletcher, CV Mofenson, LM Palumbo, PE Kang, MH Fenton, T Sapan, CV Meyer, WA Shearer, WT Hawkins, E Fowler, MG Bouquin, P Purdue, L Sloand, EM Nemo, GJ Wara, D Bryson, YJ Starr, SE Petru, A Burchett, S
Citation: Er. Stiehm et al., Use of human immunodeficiency virus (HIV) human hyperimmune immunoglobulinin HIV type 1-infected children (Pediatric AIDS Clinical Trials Group Protocol 273), J INFEC DIS, 181(2), 2000, pp. 548-554
Simultaneous HPLC assay for quantification of indinavir, nelfinavir, ritonavir, and saquinavir in human plasma
Authors: Remmel, RP Kawle, SP Weller, D Fletcher, CV
Citation: Rp. Remmel et al., Simultaneous HPLC assay for quantification of indinavir, nelfinavir, ritonavir, and saquinavir in human plasma, CLIN CHEM, 46(1), 2000, pp. 73-81
Pharmacologic considerations for therapeutic success with antiretroviral agents
Authors: Fletcher, CV
Citation: Cv. Fletcher, Pharmacologic considerations for therapeutic success with antiretroviral agents, ANN PHARMAC, 33(9), 1999, pp. 989-995
Indinavir concentrations and antiviral effect
Authors: Acosta, EP Henry, K Baken, L Page, LM Fletcher, CV
Citation: Ep. Acosta et al., Indinavir concentrations and antiviral effect, PHARMACOTHE, 19(6), 1999, pp. 708-712
Nucleoside reverse transcriptase inhibitor-induced mitochondrial toxicity as an etiology for lipodystrophy
Authors: Kakuda, TN Brundage, RC Anderson, PL Fletcher, CV
Citation: Tn. Kakuda et al., Nucleoside reverse transcriptase inhibitor-induced mitochondrial toxicity as an etiology for lipodystrophy, AIDS, 13(16), 1999, pp. 2311-2312
A phase I study of abacavir (1592U89) alone and in combination with other antiretroviral agents in infants and children with human immunodeficiency virus infection
Authors: Kline, MW Blanchard, S Fletcher, CV Shenep, JL McKinney, RE Brundage, RC Culnane, M Van Dyke, RB Dankner, WM Kovacs, A McDowell, JA Hetherington, S
Citation: Mw. Kline et al., A phase I study of abacavir (1592U89) alone and in combination with other antiretroviral agents in infants and children with human immunodeficiency virus infection, PEDIATRICS, 103(4), 1999, pp. E471-E475
Combination therapy with efavirenz, nelfinavir, and nucleoside reverse-transcriptase inhibitors in children infected with human immunodeficiency virus type 1
Authors: Starr, SE Fletcher, CV Spector, SA Yong, FH Fenton, T Brundage, RC Manion, D Ruiz, NM Gersten, M Becker, M McNamara, J Mofenson, LM
Citation: Se. Starr et al., Combination therapy with efavirenz, nelfinavir, and nucleoside reverse-transcriptase inhibitors in children infected with human immunodeficiency virus type 1, N ENG J MED, 341(25), 1999, pp. 1874-1881
Potential confusion with antiretroviral drugs
Authors: Kakuda, TN Acosta, EP Fletcher, CV
Citation: Tn. Kakuda et al., Potential confusion with antiretroviral drugs, AM J HEAL S, 55(24), 1998, pp. 2639-2640
Risultati: 1-22 |